Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib.

Janjetovic S, Asemissen AM, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P.

Tumori. 2019 Apr 1:300891619839473. doi: 10.1177/0300891619839473. [Epub ahead of print]

PMID:
30935343
2.

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

Mährle T, Akyüz N, Fuchs P, Bonzanni N, Simnica D, Germing U, Asemissen AM, Jann JC, Nolte F, Hofmann WK, Nowak D, Binder M.

Haematologica. 2019 Jul;104(7):1355-1364. doi: 10.3324/haematol.2018.208223. Epub 2019 Jan 17.

3.

The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.

Asemissen AM, Dierlamm J.

Blood. 2017 Sep 7;130(10):1274. doi: 10.1182/blood-2017-05-782714. No abstract available.

4.

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker.

Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford CT, Asemissen AM, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M.

Int J Cancer. 2017 Jun 1;140(11):2535-2544. doi: 10.1002/ijc.30549. Epub 2017 Mar 6.

5.

If it ain't broke, don't fix it!

Asemissen AM, Giagounidis A.

Haematologica. 2011 Nov;96(11):e44. doi: 10.3324/haematol.2011.050872. No abstract available.

6.

Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.

Busse A, Asemissen AM, Nonnenmacher A, Braun F, Ochsenreither S, Stather D, Fusi A, Schmittel A, Miller K, Thiel E, Keilholz U.

Eur J Cancer. 2011 Mar;47(5):690-6. doi: 10.1016/j.ejca.2010.11.021. Epub 2011 Jan 5.

PMID:
21215610
7.

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C.

Blood. 2009 Jun 25;113(26):6541-8. doi: 10.1182/blood-2009-02-202598. Epub 2009 Apr 23.

8.

Vaccination strategies in patients with renal cell carcinoma.

Asemissen AM, Brossart P.

Cancer Immunol Immunother. 2009 Jul;58(7):1169-74. doi: 10.1007/s00262-009-0706-7. Epub 2009 Apr 10.

PMID:
19360405
9.

Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2.

Asemissen AM, Haase D, Stevanovic S, Bauer S, Busse A, Thiel E, Rammensee HG, Keilholz U, Scheibenbogen C.

J Immunother. 2009 May;32(4):370-5. doi: 10.1097/CJI.0b013e31819d4e09.

PMID:
19342968
10.

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.

Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U.

Oncology. 2009;76(5):350-4. doi: 10.1159/000209961. Epub 2009 Mar 24.

PMID:
19321976
11.

CMV-specific central memory T cells reside in bone marrow.

Letsch A, Knoedler M, Na IK, Kern F, Asemissen AM, Keilholz U, Loesch M, Thiel E, Volk HD, Scheibenbogen C.

Eur J Immunol. 2007 Nov;37(11):3063-8.

12.

Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.

Asemissen AM, Keilholz U, Tenzer S, Müller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C.

Clin Cancer Res. 2006 Dec 15;12(24):7476-82.

13.

Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae.

Wadle A, Held G, Neumann F, Kleber S, Wuellner B, Asemissen AM, Kubuschok B, Scheibenbogen C, Breinig T, Meyerhans A, Renner C.

Vaccine. 2006 Sep 11;24(37-39):6272-81. Epub 2006 Jun 14.

PMID:
16860448
14.

Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells.

Na IK, Keilholz U, Letsch A, Bauer S, Asemissen AM, Nagorsen D, Thiel E, Scheibenbogen C.

Cancer Immunol Immunother. 2007 Mar;56(3):391-6. Epub 2006 Jul 19.

PMID:
16850346
15.

Specific central memory T cells in the bone marrow of patients immunized against tyrosinase peptides.

Letsch A, Keilholz U, Kern F, Asemissen AM, Thiel E, Scheibenbogen C.

J Immunother. 2006 Mar-Apr;29(2):201-7.

PMID:
16531820
16.

Malignant melanoma--clinical development of peptide-based melanoma vaccines.

Schmittel A, Scheibenbogen C, Letsch A, Asemissen AM, Thiel E, Keilholz U.

Front Radiat Ther Oncol. 2006;39:171-180. doi: 10.1159/000090861. Review. No abstract available.

PMID:
16394680
17.

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2.

Godal R, Keilholz U, Uharek L, Letsch A, Asemissen AM, Busse A, Na IK, Thiel E, Scheibenbogen C.

Blood. 2006 Apr 15;107(8):3205-11. Epub 2005 Dec 22.

18.

CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets.

Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E, Uharek L.

Leukemia. 2005 May;19(5):835-40.

PMID:
15744340
19.
20.

Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients.

Letsch A, Keilholz U, Fluck M, Nagorsen D, Asemissen AM, Schmittel A, Thiel E, Scheibenbogen C.

Int J Cancer. 2005 May 10;114(6):936-41.

21.

Functional CCR9 expression is associated with small intestinal metastasis.

Letsch A, Keilholz U, Schadendorf D, Assfalg G, Asemissen AM, Thiel E, Scheibenbogen C.

J Invest Dermatol. 2004 Mar;122(3):685-90.

22.

Rational peptide-based tumour vaccine development and T cell monitoring.

Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U.

Semin Cancer Biol. 2003 Dec;13(6):423-9. Review.

PMID:
15001161
23.

Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.

Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG, Schadendorf D.

Int J Cancer. 2002 Mar 20;98(3):409-14.

24.

Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.

Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Liénard D, Keilholz U.

Cancer Res. 2002 Mar 15;62(6):1743-50.

25.

Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells.

Asemissen AM, Nagorsen D, Keilholz U, Letsch A, Schmittel A, Thiel E, Scheibenbogen C.

J Immunol Methods. 2001 May 1;251(1-2):101-8.

PMID:
11292486
26.

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C.

Cancer Res. 2000 Sep 1;60(17):4850-4.

Supplemental Content

Loading ...
Support Center